Posted: March 29, 2018
An HIV Success Story
Mylan continues to fight for access to high-quality medicine and one of our best success stories is for people living with HIV. While I continue to be an advocate to fix our broken healthcare system and work to find solutions for the patient at the pharmacy counter, I equally want to call attention to what is working.
For a decade, Mylan has been at the forefront of expanding access to more affordable antiretrovirals. In addition to our already-strong portfolio of ARVs in developing markets, this year we are introducing three new single-tablet regimens in the U.S., including an approval we announced this week. Total U.S. spending for HIV medications exceeds $20 billion annually, and HIV is a top cost driver for many healthcare payers. Mylan's goal is to reduce these costs and empower patients to choose a lower-cost ARV treatment option that is right for them. Visit newsroom.mylan.com to read our recent press releases.
There is nothing more rewarding than receiving feedback from the HIV advocacy community on how these products will help lower costs for patients and the overall U.S. healthcare system. The positive response we’ve received thus far inspires us in our continued efforts to satisfy the unmet needs of people living with HIV in the U.S. and around the world.